# Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer

> **NCT02900560** · PHASE2 · TERMINATED · sponsor: **Translational Research in Oncology** · enrollment: 34 (actual)

## Conditions studied

- Epithelial Ovarian Cancer

## Interventions

- **DRUG:** CC-486
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02900560
- **Lead sponsor:** Translational Research in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-12-20
- **Primary completion:** 2021-05-27
- **Final completion:** 2021-05-27
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2022-06-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02900560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02900560, "Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02900560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*